Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for nonclostridial toxin target cells

Details for Australian Patent Application No. 2007272517 (hide)

Owner Allergan, Inc.

Inventors Steward, Lance E.; Li, Shengwen; Francis, Joseph; Fernandez-Salas, Ester; Gilmore, Marcella A.; Aoki, Kei Roger

Agent Davies Collison Cave

Pub. Number AU-A-2007272517

PCT Pub. Number WO2008/008805

Priority 60/807,059 11.07.06 US

Filing date 11 July 2007

Wipo publication date 17 January 2008

International Classifications

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

C07K 14/43 (2006.01) Peptides having more than 20 amino acids

Event Publications

5 February 2009 PCT application entered the National Phase

  PCT publication WO2008/008805 Priority application(s): WO2008/008805

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007272521-Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling

2007272515-Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells